13 June 2024
13 June 2024
The CIFFREO study is under a dosing pause due to a fatal serious adverse event reported in the Phase II DAYLIGHT trial.
Recent trends highlight a surge in demand for mass market medicines. This increase is driven by lessons from the Covid-19 pandemic, when vaccines had to be made available quickly in large quantities, but also from the ongoing need for diabetes or weight loss medication.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
